|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003315,
umls-concept:C0003320,
umls-concept:C0008269,
umls-concept:C0019627,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0039194,
umls-concept:C0178539,
umls-concept:C0205164,
umls-concept:C0205227,
umls-concept:C0282580,
umls-concept:C0349590,
umls-concept:C0439659,
umls-concept:C0449450,
umls-concept:C0456387,
umls-concept:C1548673,
umls-concept:C2003874
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1994-3-15
|
|
pubmed:abstractText |
Chloroquine treatment of antigen-presenting cells (APC) was explored as a tool to investigate the processing pathway for major histocompatibility complex (MHC) class II-restricted presentation of the endogenous secreted hen egg lysozyme (HEL) and transmembrane measles virus haemagglutinin (HA). A 72-hr pretreatment of the APC with 25 microM chloroquine blocked the presentation of the HEL(52-61) T-cell epitope generated from endogenous HEL to the I-Ak-restricted 3A9 T-cell hybridoma by MHC class II-transfected L cells expressing the invariant chain (Ii). The presentation of exogenously added HEL peptides was not affected. Under the same conditions, no inhibition of the presentation of HEL(106-116) to the I-Ed-restricted G28 high-avidity T-cell hybridoma, nor of HA when synthesized by L cells, was observed. When B-lymphoid APC were used, inhibition was observed in every case with a low number of B APC pretreated for 48 hr with chloroquine prior to the T-cell stimulation test. Moreover, addition of chloroquine to untreated B APC during the T-cell stimulation assay was sufficient to inhibit completely the presentation of HEL(106-116) to the B10.D24.42 low avidity T-cell hybridoma. Altogether these studies suggest that an apparent resistance of endogenous Ag presentation to chloroquine inhibition may not necessarily indicate the existence of a non-endosomal pathway but may be due to the nature of the T-cell epitope, to the use of 'non-professional' APC such as L cells, to the use of T cells of high avidity, and to high amounts of pre-existing MHC class II-peptide complexes expressed by the APC. We demonstrate here that, at least in conventional APC such as B cells, class II-restricted presentation of both endogenous secreted HEL and transmembrane HA involves an endosomal pathway.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1336977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1379172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1549591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1549594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1613454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1614517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1655000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1656276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1721638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1737924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1913812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1922338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1967486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1968506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-1976509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2117634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2166918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2388037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2452090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2456369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2492101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-2945825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-3257576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-6166712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-6183281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-6361463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7508420-8495491
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0019-2805
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
566-73
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7508420-Animals,
pubmed-meshheading:7508420-Antigen Presentation,
pubmed-meshheading:7508420-Antigen-Presenting Cells,
pubmed-meshheading:7508420-B-Lymphocytes,
pubmed-meshheading:7508420-Cells, Cultured,
pubmed-meshheading:7508420-Chloroquine,
pubmed-meshheading:7508420-Dose-Response Relationship, Immunologic,
pubmed-meshheading:7508420-Epitopes,
pubmed-meshheading:7508420-Fibroblasts,
pubmed-meshheading:7508420-Hemagglutinins, Viral,
pubmed-meshheading:7508420-Histocompatibility Antigens Class II,
pubmed-meshheading:7508420-Mice,
pubmed-meshheading:7508420-Muramidase,
pubmed-meshheading:7508420-T-Lymphocytes,
pubmed-meshheading:7508420-Time Factors
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
|
|
pubmed:affiliation |
Department of Microbiology and Molecular Genetics, UCLA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
